General Information
Version
9
Revision date
2023-09-25
Product name
Propiophenone
Product Synonyms
Ethyl phenyl ketone; 1-Phenyl-1-propanone
CAS No.
93-55-0
REACH No
01-2119960630-41
Emergency telephone
001-800-227-6701, +32 14 57 52 11, 001-201-796-7100, +32 14 57 52 99, 001-800-424-9300, 001-703-527-3887
Icons in SDS
Company Information
company name
Fisher Scientific UK
e-mail address of the competent person responsible for the Safety Data Sheet
begel.sdsdesk@thermofisher.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H319
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
CLP Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567 Classification of the substance or mixture
Physical hazards
Based on available data, the classification criteria are not met
Health hazards
Serious Eye Damage/Eye Irritation Category 2 (H319)
Environmental hazards
Based on available data, the classification criteria are not met Full text of Hazard Statements: see section 16
Signal word
Warning
Hazard statements
H319 - Causes serious eye irritation Combustible liquid
Precautionary statements
P264 - Wash face, hands and any exposed skin thoroughly after handling P280 - Wear eye protection/ face protection P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing P337 + P313 - If eye irritation persists: Get medical advice/attention
2.3 Other hazards
No information available This product does not contain any known or suspected endocrine disruptors
2.1 Classification of the substance or mixture
CLP Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567 Physical hazards Based on available data, the classification criteria are not met Health hazards Serious Eye Damage/Eye Irritation Category 2 (H319) Environmental hazards Based on available data, the classification criteria are not met Full text of Hazard Statements: see section 16
